Navigation Links
VETORYL(R) (Trilostane) Receives FDA Approval
Date:12/15/2008

OVERLAND PARK, Kan., Dec. 15 /PRNewswire/ -- Dechra Veterinary Products LLC today announces that the company has received FDA approval to market VETORYL(R) Capsules.

VETORYL Capsules contain the drug trilostane, which has been demonstrated to be effective in the treatment of Cushing's syndrome in dogs. VETORYL will be indicated for use in pituitary-dependent hyperadrenocorticism, which comprises the majority of cases of Cushing's syndrome in dogs. Additionally, VETORYL has received designation status as a Minor Use Drug for treatment of hyperadrenocorticism caused by adrenal tumors -- the first drug to receive an approval for this indication and the first drug to receive a Minor Use designation in dogs.

Mike Eldred, President of U.S. Operations, says, "We are very excited to have approval to market this novel product in the U.S. Following its launch in January, veterinarians will be able to source the product through our network of distribution partners."

Dechra Veterinary Products LLC, located in Overland Park, Kansas, is the U.S. subsidiary of Dechra Pharmaceuticals PLC, a UK listed company focused on international animal healthcare markets. Dechra currently markets a range of specialized veterinary products in the U.S. For more information, please visit http://www.dechra-us.com or call 866-933-2472.


'/>"/>
SOURCE Dechra Veterinary Products LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
2. DaVita Receives Civil Complaint
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
4. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
5. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
6. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
7. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
8. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
9. Prime Therapeutics Receives TIPPS Certification
10. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
11. UCLA receives $22.5 million to explore the fundamental biology of mental disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
Breaking Medicine Technology: